摘要
目的了解鲍氏不动杆菌的耐药现状及其对头孢哌酮/舒巴坦的耐药特性,为抗菌药物的选用提供依据。方法回顾性调查2007-2011年每年1-5月分离的鲍氏不动杆菌临床分布情况;应用VITEK-60全自动微生物分析仪检测鲍氏不动杆菌对常用抗菌药物的耐药性,琼脂稀释法检测头孢哌酮/舒巴坦的最低抑菌浓度(MIC)。结果 603株鲍氏不动杆菌主要来源于呼吸道标本,占90.4%,且主要集中于几个重症监护病区,占70.3%;除头孢哌酮/舒巴坦外,鲍氏不动杆菌对其他临床常用抗菌药物的耐药性率均>60.0%,而头孢哌酮/舒巴坦非耐药株中,近年来处于中介的比例>50.0%。结论鲍氏不动杆菌临床分离株的标本来源和病区分布均有明显集中趋势,其临床常用抗菌药物耐药严重,头孢哌酮/舒巴坦非耐药株的MIC值明显增高,需引起关注。
OBJECTIVE To investigate the drug resistance of Acinetobacter baumannii and to evaluate the characteristic of resistance against cefoperazone/sulbactam.METHODS Retrospective survey was used to study the distribution of A.baumannii in our hospital from Jan.2007 to May.2011;VITEK-60 AMS was used to detect the susceptibility of A.baumannii against ciprofloxacin,ceftriaxone,ceftazidime,gentamicin,tobramycin,SMZ-TMP,ampicillin/sulbactam,piperacillin/tazobactam and imipenem.Agar dilution method was used to detect the minimum inhibitory concentration（MIC） of cefoperazone/sulbactam.RESULTS A total of 603 strains of A.baumannii were isolated from respiratory tract,accounting for 90.4% and the most risky area was intensive care unit（70.3%）.The resistance rate of A.baumannii exceeded 60.0% against clinical frequently used antibiotics except for cefoperazone/sulbactam.The ratio of intermediate exceed 50.0% in cefoperazone/sulbactam un-resistant strains.CONCLUSION A.baumannii tends to distribute in some common sites and comes from the same sources,The drug resistance of A.baumannii is high.The MIC is increasing of strains un-resistant to cefoperazone/sulbactam.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2012年第4期803-805,共3页
Chinese Journal of Nosocomiology
基金
浙江省卫生厅资助项目(2011KYA106)
